Keywords
Pruritus
Prevalence
Epidemiology
Argentina
How to Cite
Abstract
OBJECTIVE: To describe the prevalence and epidemiological and clinical characteristics of patients with chronic prurigo.
METHODS: A descriptive, cross-sectional study was conducted on adult patients enrolled in the Medical Care Program of the Hospital Italiano de Buenos Aires, Argentina (PMHI), between January 1, 2018, and January 1, 2023.
RESULTS: 132,535 patients were registered, of whom 144 had chronic prurigo; 105 (73%) were women with a median age of 67.5 years (IQR 51-79). The point prevalence of chronic prurigo was 0.11% (95% CI: 0.09-0.13%), significantly higher in women than in men (0.13% [95% CI: 0.11-0.16%] vs 0.07% [95% CI: 0.05-0.09%], p<0.0006). The most frequent manifestations were papules (90%) and excoriations (84.7%), followed by plaques (21.5%) and nodules (18.7%). The median time to diagnosis was 168 days (IQR 36-765). The most frequently prescribed treatments were emollients, topical corticosteroids, and antihistamines.
CONCLUSIONS: The prevalence of chronic prurigo in our cohort differs from that reported in other countries. Unlike previous studies, no statistically significant associations with other skin diseases were found. The treatment the patients received was inconsistent with that proposed in international guidelines.
KEYWORDS: Prurigo; Pruritus; Prevalence; Epidemiology; Argentina.
References
1. Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021; 84 (3): 747-760. doi:10.1016/j.jaad.2020.07.025.
2. Morgan CLL, Thomas M, Ständer S, et al. Epidemiology of prurigo nodularis in England: a retrospective database analysis. Br J Dermatol. 2022; 187 (2):188-195. doi:10.1111/bjd.21032.
3. Furue M, Yamazaki S, Jimbow K, et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol. 2011; 38 (4): 310-320. doi:10.1111/j.1346-8138.2011.01209.x.
4. Ryczek A, Reich A. Prevalence of prurigo nodularis in Poland. Acta Derm Venereol. 2020; 100 (10): adv00155. doi:10.2340/00015555-3518.
5. Pereira MP, Zeidler C, Wallengren J, et al. Chronic nodular prurigo: a European cross-sectional study of patient perspectives on therapeutic goals and satisfaction. Acta Derm Venereol. 2021; 101 (2): adv00403. doi:10.2340/00015555-3726.
6. Boozalis E, Tang O, Patel S, Semenov YR, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol. 2018; 79 (4): 714-719.e3. doi:10.1016/j.jaad.2018.04.047.
7. Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: Pathogenesis and management. J Am Acad Dermatol. 2020; 83: 1567-1575. doi:10.1016/j.jaad.2020.04.182.
8. Valdman-Grinshpoun Y, Zaga A, Cohen AD, Schonmann Y, et al. Comorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross-Sectional Population-Based Analysis. Int J Dermatol. 2025. doi: 10.1111/ijd.70107.
9. Von Kiedrowski R, Metz M, Weisshaar E, Albrecht I, et al. Evaluation of routine care of prurigo nodularis in Germany: retrospective chart review study (ADVANCE PN). J Dtsch Dermatol Ges. 2025; 23 (7): 844-855. doi: 10.1111/ddg.15721.
10. Vázquez-López F, González-López M, Pérez-Oliva N. Las lesiones elementales en la dermatología española actual (II): paradigmas semánticos. Actas Dermo‑Sifiliográficas 2001; 92 (1): 47‑52. doi: 10.1016/S0001-7310(01)79142-9.
11. Joel MZ, Hydol-Smith J, Kambala A, Cornman HL, Kwatra SG. Prevalence and comorbidity burden of prurigo nodularis in United States adults enrolled in the All of Us research program. J Am Acad Dermatol. 2023; 89 (5): 1056-1058. doi: 10.1016/j.jaad.2023.06.045.
12. Müller S, Zeidler C, Ständer S. Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments. Am J Clin Dermatol. 2024; 25 (1): 15-33. doi: 10.1007/s40257-023-00818-z.
13. Kwatra SG, Pereira MP, Misery L, Mollanazar NK, et al. Prurigo nodularis: disease burden, clinical features and approach to management. Br J Dermatol. 2025; 193 (4): 642-652. doi: 10.1093/bjd/ljaf213.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2026 Revista Alergia México